Get the Stockscreener App
3.27
1.55%
0.05
After Hours:
3.27
Voyager Therapeutics Inc stock is traded at $3.27, with a volume of 305.58K.
It is up +1.55% in the last 24 hours and up +3.48% over the past month.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$3.22
Open:
$3.22
24h Volume:
305.58K
Relative Volume:
0.49
Market Cap:
$201.49M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-1.6028
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+0.00%
1M Performance:
+3.48%
6M Performance:
-3.54%
1Y Performance:
-12.10%
1-Day Range:
$3.135
$3.29
1-Week Range:
$3.135
$3.33
52-Week Range:
$2.935
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.27 | 197.18M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - stocktitan.net
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Moomoo
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Voyager Reports Second Quarter 2026 Financial and Operating Results - The Manila Times
Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028 - TradingView
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows - TradingView
Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706 - Stock Titan
VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION - Moomoo
Voyager Therapeutics (VYGR) Edges Higher by 1.45% as Shares Defend $2.99 SupportFibonacci Arc - dars.gov.et
Voyager Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR): Millennium entities disclose 7.4% beneficial stake in Schedule 13G/A - stocktitan.net
Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday - MarketBeat
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYGR|Voyager Therapeutics Inc|Price:3.090|Chg%:-0.010 - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Cash Flow - TradingKey
TradingKey - TradingKey
Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR - TradingView
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data - Investing.com Nigeria
Voyager Therapeutics (VYGR) Dips 3.79% as Shares Test Support Near $3.0Max Pain Level - dars.gov.et
Voyager’s gene therapy reduces tau levels in AD models - BioWorld News
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - Sahm
Voyager Therapeutics advances tau-silencing gene therapy program - TipRanks
Voyager reports VY1706 Alzheimer’s therapy data - grafa.com
Voyager Therapeutics Presents Positive GLP Toxicology Data for VY1706 Tau Silencing Gene Therapy in Alzheimer’s Disease, Plans Clinical Trial in 2026 – Minichart - Minichart
Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus
Voyager presents six-month data for Alzheimer’s gene therapy By Investing.com - Investing.com Nigeria
[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan
Voyager presents six-month data for Alzheimer’s gene therapy - Investing.com
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 - GlobeNewswire
Single-dose Alzheimer’s gene therapy from Voyager lowers brain tau in primates - stocktitan.net
Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):